Allogene Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
13.9%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$0.61next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| ALLO-329 RESOLUTION Trial Phase 1 Data Update | 31 Dec 2026 |
| ALPHA3 Trial Event-Free Survival Interim Analysis | 30 Jun 2027 |
Monitoring Framework
Key Performance Indicators
ALPHA3 Trial Minimal Residual Disease (MRD) Clearance Rate Quarterly5,830.0%Target: 25% to 30% absolute improvement over observation arm
Cash Runway (Years of Funding) Quarterly3.0Target: Maintain sufficient capital to fund operations through key clinical readouts
ALLO-316 Phase 1 TRAVERSE Trial Response Rate in CD70+ Renal Cell Carcinoma Annually3,100.0%Target: Demonstrate competitive efficacy in solid tumors
Watch Items
- ALPHA3 Trial Event-Free Survival (EFS) Interim AnalysisTrigger: Mid-2027 interim analysis of EFSAction: Evaluate clinical efficacy data to support potential BLA submission
- ALLO-329 Phase 1 RESOLUTION Trial Proof-of-Concept DataTrigger: Initial biomarker, CAR T expansion, and clinical outcome readoutsAction: Assess the viability of the Dagger platform in reducing or eliminating chemotherapy-based lymphodepletion
- CEO Succession TransitionTrigger: Effective date of July 1, 2026Action: Monitor operational execution and clinical pipeline momentum under incoming CEO Dr. Zachary Roberts
Research as of 20 Jun 2026